In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biomatrix Inc.

Division of Sanofi
www.biomatrix.com

Latest From Biomatrix Inc.

Biomaterials: How Compelling is the Opportunity?

As the points of intersection between the biotechnology and medical device industries increase, biomaterials theoretically represent a significant investment opportunity. Yet, to date, there have been no biomaterial company successes comparable to the "Intel inside" phenomenon in the electronics industry.
Medical Device Business Strategies

Focal Seals its Fate

Investors in biomedical stocks are a tough crowd. They want to see current revenue streams and a pipeline of large-market products. Unfortunately, surgical sealant developer Focal Inc. provided neither to a sufficient degree. In early May, Focal agreed to merge into Genzyme Biosurgery in a stock swap transaction. The modest purchase price of $12 million bears witness to the fact that Focal simply did not do a good job of making the transition from a technology developer to a product manufacturer, at least not in the timeframe of investors.
Medical Device Business Strategies

The Bricks and Mortar of Personalized Medicine

With an increasing number of therapies derived from a patient's own cells, companies now have experience to draw on in designing commercial infrastructures for delivering these un-drug-like products. Indeed, armed with some small experience around how well they fit--or don't fit--into standard medical practice, cell-based therapies may finally be going commercial. And not only in terms of a transition from acute to chronic wound healing indications, where commercial success was first anticipated, but also as stem cell therapies, which would open up a multi-billon dollar opportunity in regenerative medicine, including replacements for organ and transplant surgery and cures for diabetes and neurological diseases such as Parkinson's Disease and Alzheimer's Disease, as well as autologous cancer immunotherapies. These companies are finding value in the experiences of earlier, technology-constrained companies whose attempts at developing cell therapies failed--Applied Immune Sciences and Systemix Inc., for example, both of which have virtually disappeared. Companies today are trying to overcome the challenges of product preparation, process standardization, and delivery. Other first generation cell therapy companies, like Genzyme Tissue Repair and Cell Genesys Inc., are still around. That a number of senior executives at today's leading-edge cell-therapy companies cut their eye teeth at those first-generation start-ups attests to their continuing belief in the broad commercial opportunities these technologies offer. But significant questions remain: Can companies solve the production economics of delivering products that require cell culture and expansion using a centralized, company-controlled laboratory model? The alternative, a decentralized technology transfer approach, would bring the product closer to the patient, but raises the question of whether the technology exists to standardize processes and satisfy regulators' quality concerns. Then, if these issues are solved, one must ask whether a hospital lab is the right setting for a commercial operation. Are there better commercial infrastructures, such as blood processing centers, with which companies could form alliances? And does the prospect of developing off-the-shelf, allogeneic-cell therapies-mass-produced stem cells that can pass the immune system undetected or vaccines derived from shared tumor antigens from cell lines, for example-threaten to obsolete autologous products before they become profitable?
BioPharmaceutical Strategy

Genzyme Bets Big on Biosurgery

Genzyme Corp is merging two of its subsidiaries, Genzyme Tissue Repair and Genzyme Surgical with a third company, Biomatrix Inc. in a bold bet on the promise of biosurgery--the combination of biomaterials and gene and cellular therapies with more traditional surgical instruments. Clinically, biosurgery will hopefully improve patient outcomes; commercially, it will differentiate surgical instrument makers whose products seem increasingly alike.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
  • Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sanofi
  • Senior Management
  • Endre A Balazs, MD, CEO & CSO
    Rory A Riggs, Pres. & Acting CFO
    Janet L Denlinger, PhD, EVP
    Martin Jordan, Dir., Intl. Mkt. Dev.
    Nancy E Larsen, PhD, Deputy CSO
  • Contact Info
  • Biomatrix Inc.
    Phone: (201) 945-9550
    65 Railroad Ave.
    Ridgefield, NJ 07657
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register